A. Sinclair Dunlop Apellis Pharmaceuticals, Inc. (APLS) insider trading activity

APLS Quotes by TradingView

A. Sinclair Dunlop is Director of Apellis Pharmaceuticals, Inc.. Currently has a direct ownership of 152,126 shares of APLS, which is worth approximately $4.37 Million. The most recent transaction as insider was on Sep 23, 2024, when has been sold 4,600 shares (Common Stock) at a price of $13.19 per share, resulting in proceeds of $60,674. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 152K
13.17% 3M change
15.86% 12M change
Total Value Held $4.37 Million

A. Sinclair Dunlop Transaction History

Date Transaction Value Shares Traded Shares Held Form
Sep 23 2024
BUY
Exercise of conversion of derivative security
$60,674 $13.19 p/Share
4,600 Added 2.94%
152,126 Common Stock
Jun 28 2024
BUY
Exercise of conversion of derivative security
$11,871 $13.19 p/Share
900 Added 0.67%
134,418 Common Stock
Apr 12 2024
BUY
Exercise of conversion of derivative security
$19,785 $13.19 p/Share
1,500 Added 1.11%
133,518 Common Stock
Jan 01 2024
BUY
Grant, award, or other acquisition
-
3,341 Added 2.47%
132,018 Common Stock
Dec 14 2023
BUY
Exercise of conversion of derivative security
$82,754 $13.19 p/Share
6,274 Added 4.65%
128,677 Common Stock
Nov 17 2023
SELL
Open market or private sale
$444,611 $49.99 p/Share
8,894 Reduced 6.77%
122,403 Common Stock
Apr 03 2023
SELL
Open market or private sale
$37,025 $74.05 p/Share
500 Reduced 0.38%
131,297 Common Stock
Mar 01 2023
SELL
Open market or private sale
$32,665 $65.33 p/Share
500 Reduced 0.38%
131,797 Common Stock
Feb 01 2023
SELL
Open market or private sale
$26,305 $52.61 p/Share
500 Reduced 0.38%
132,297 Common Stock
Jan 03 2023
SELL
Open market or private sale
$25,350 $50.7 p/Share
500 Reduced 0.38%
132,797 Common Stock
Jan 01 2023
BUY
Grant, award, or other acquisition
-
3,867 Added 2.82%
133,297 Common Stock
Dec 01 2022
SELL
Open market or private sale
$24,965 $49.93 p/Share
500 Reduced 0.38%
129,430 Common Stock
Nov 01 2022
SELL
Open market or private sale
$30,415 $60.83 p/Share
500 Reduced 0.38%
129,930 Common Stock
Aug 25 2022
BUY
Exercise of conversion of derivative security
$56,796 $13.19 p/Share
4,306 Added 3.2%
130,430 Common Stock
Aug 16 2022
BUY
Exercise of conversion of derivative security
$355,516 $14.0 p/Share
25,394 Added 16.76%
126,124 Common Stock
Jul 21 2022
BUY
Exercise of conversion of derivative security
$134,484 $14.0 p/Share
9,606 Added 8.71%
100,730 Common Stock
Apr 22 2022
BUY
Exercise of conversion of derivative security
$280,000 $14.0 p/Share
20,000 Added 18.0%
91,124 Common Stock
Jan 01 2022
BUY
Grant, award, or other acquisition
-
4,230 Added 5.61%
71,124 Common Stock
Sep 10 2021
BUY
Exercise of conversion of derivative security
$96,516 $14.0 p/Share
6,894 Added 9.34%
66,894 Common Stock
Jun 01 2021
BUY
Other acquisition or disposition
-
13,108 Added 15.2%
73,108 Common Stock
Apr 23 2021
BUY
Exercise of conversion of derivative security
$140,000 $14.0 p/Share
10,000 Added 14.29%
60,000 Common Stock
Apr 16 2021
BUY
Exercise of conversion of derivative security
$700,000 $14.0 p/Share
50,000 Added 50.0%
50,000 Common Stock
ASD

A. Sinclair Dunlop

Director
Waltham, MA

Track Institutional and Insider Activities on APLS

Follow Apellis Pharmaceuticals, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells APLS shares.

Notify only if

Insider Trading

Get notified when an Apellis Pharmaceuticals, Inc. insider buys or sells APLS shares.

Notify only if

News

Receive news related to Apellis Pharmaceuticals, Inc.

Choose your preferred platform and Sign Up 👇 Telegram Email
Track Activities on APLS